IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v4y2020i1d10.1007_s41669-019-0166-8.html
   My bibliography  Save this article

Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis

Author

Listed:
  • Paola Rucci

    (Alma Mater Studiorum University of Bologna)

  • Vera Maria Avaldi

    (Alma Mater Studiorum University of Bologna)

  • Claudio Travaglini

    (Alma Mater Studiorum University of Bologna)

  • Cristina Ugolini

    (Alma Mater Studiorum University of Bologna)

  • Elena Berti

    (Regional Agency for Health and Social Care)

  • Maria Luisa Moro

    (Regional Agency for Health and Social Care)

  • Maria Pia Fantini

    (Alma Mater Studiorum University of Bologna)

Abstract

Background and Objectives Many studies and systematic reviews have estimated the healthcare costs of diabetes using a cost-of-illness approach. However, in the studies based on this approach patients’ heterogeneity is rarely taken into account. The aim of this study was to stratify patients with type 2 diabetes into homogeneous cost groups based on demographic and clinical characteristics. Methods We conducted a retrospective cost-of-illness study by linking individual data on health services utilization retrieved from the administrative databases of Emilia-Romagna Region (Italy). Direct medical costs (either all-cause or diabetes-related) were calculated from the perspective of the regional health service, using tariffs for hospitalizations and outpatient services and the unit costs of prescriptions for drugs. The determinants of costs identified in a generalized linear regression model were used to characterize subgroups of patients with homogeneous costs in a classification and regression tree analysis. Results The study population consisted of a cohort of 101,334 patients with type 2 diabetes, followed up for 1 year, with a mean age of 70.9 years. Age, gender, complications, comorbidities and living area accounted significantly for cost variability. The classification tree identified ten patient subgroups with different costs, ranging from a median of €483 to €39,578. The two subgroups with highest costs comprised dialysis patients, and the largest subgroup (57.9%) comprised patients aged ≥ 65 years without renal, cardiovascular and cerebrovascular complications. Conclusions Classification of patients into homogeneous cost subgroups can be used to improve the management of, and budget allocation for, patients with type 2 diabetes.

Suggested Citation

  • Paola Rucci & Vera Maria Avaldi & Claudio Travaglini & Cristina Ugolini & Elena Berti & Maria Luisa Moro & Maria Pia Fantini, 2020. "Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis," PharmacoEconomics - Open, Springer, vol. 4(1), pages 181-190, March.
  • Handle: RePEc:spr:pharmo:v:4:y:2020:i:1:d:10.1007_s41669-019-0166-8
    DOI: 10.1007/s41669-019-0166-8
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-019-0166-8
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-019-0166-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Simon Condliffe & Charles R. Link & Shreekant Parasuraman & Michael F. Pollack, 2013. "The effects of hypertension and obesity on total health-care expenditures of diabetes patients in the United States," Applied Economics Letters, Taylor & Francis Journals, vol. 20(7), pages 649-652, May.
    2. A. Marcellusi & R. Viti & A. Mecozzi & F. Mennini, 2016. "The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(2), pages 139-147, March.
    3. Jason Yeaw & Shawn Halinan & Dionne Hines & Amy DeLozier & Magaly Perez & Mark Boye & Kristina Boye & Christopher Blanchette, 2014. "Direct Medical Costs for Complications Among Children and Adults with Diabetes in the US Commercial Payer Setting," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 219-230, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Elizabeth Wehler & Dominik Lautsch & Stacey Kowal & Glenn Davies & Andrew Briggs & Qianyi Li & Swapnil Rajpathak & Adnan Alsumali, 2021. "Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin," PharmacoEconomics, Springer, vol. 39(3), pages 317-330, March.
    2. J. Pöhlmann & K. Norrbacka & K. S. Boye & W. J. Valentine & H. Sapin, 2020. "Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1179-1196, November.
    3. Till Seuring & Olga Archangelidi & Marc Suhrcke, 2015. "The Economic Costs of Type 2 Diabetes: A Global Systematic Review," PharmacoEconomics, Springer, vol. 33(8), pages 811-831, August.
    4. François-Olivier Baudot & Anne-Sophie Aguadé & Thomas Barnay & Christelle Gastaldi-Ménager & Anne Fagot-Campagna, 2019. "Impact of type 2 diabetes on health expenditure: estimation based on individual administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(5), pages 657-668, July.
    5. Mennini, Francesco Saverio & Gitto, Lara, 2022. "Approaches to Estimating Indirect Costs in Healthcare: Motivations for Choice," MPRA Paper 112129, University Library of Munich, Germany.
    6. Margherita d’Errico & Milena Pavlova & Federico Spandonaro, 2022. "The economic burden of obesity in Italy: a cost-of-illness study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 177-192, March.
    7. A. Marcellusi & F. S. Mennini & P. Sciattella & G. Favato, 2021. "Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1371-1379, December.
    8. G. Fabiano & A. Marcellusi & F. S. Mennini & P. Sciattella & G. Favato, 2023. "Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(1), pages 75-80, February.
    9. Francesca Lazzarini & Luca Barbacane & Giuseppe Scoleri & Rosanna I. Comoretto & Gianni Cogno & Benedetta Disarò & Luigi Gomirato & Francesca Stocco & Alessandro Suppa & Gianluca Toninato & Clara Mint, 2021. "Evaluating Effectiveness of Outpatient Monitoring in Type 2 Diabetes: The One-Year Experience in an Italian Group of Primary Care," IJERPH, MDPI, vol. 18(21), pages 1-10, November.
    10. Cristian Alvarez & Marcelo Tuesta & Álvaro Reyes & Francisco Guede-Rojas & Luis Peñailillo & Igor Cigarroa & Jaime Vásquez-Gómez & Johnattan Cano-Montoya & Cristóbal Durán-Marín & Oscar Rojas-Paz & Hé, 2023. "Heart Rate from Progressive Volitional Cycling Test Is Associated with Endothelial Dysfunction Outcomes in Hypertensive Chilean Adults," IJERPH, MDPI, vol. 20(5), pages 1-15, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:4:y:2020:i:1:d:10.1007_s41669-019-0166-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.